[ad_1]
Turkey will use the vaccine against the COVID-19 coronavirus infection produced by the Chinese company Sinovac for mass immunization of citizens, said the country’s Health Minister Fahretin Koca.
Turkey’s Health Minister Fahretin Koca said in a briefing on December 24 that during the investigation, a vaccine against the COVID-19 coronavirus infection produced by the Chinese company Sinovac showed an effectiveness of 91.25%. The transcript of the briefing was posted on the ministry’s website.
Koca said Turkey will use the Sinovac vaccine for mass immunization.
“Now we are confident that the vaccine is effective and safe for the Turkish people,” said the minister. According to him, the first batch of the drug will be delivered to the country on December 28.
The Hürriyet Daily News writes that Turkey has signed an agreement to buy 50 million doses of the Sinovac vaccine, in the first batch: 3 million doses.
As the minister said, vaccination against coronavirus infection in the country will be carried out in four stages, in the first 9 million people will receive vaccinations, the ministry hopes to vaccinate up to 1.5-2 million people per day. A vaccination campaign is scheduled to start in Turkey in January. Koca intends to be one of the first to be grafted.
As Hürriyet Daily News noted, Turkey also intends to receive by March 2021 4.5 million doses of vaccine produced by companies Pfizer and BioNTech, including 1.5 million doses in January.
An outbreak of coronavirus infection began in late 2019 in China. March 11, 2020 World Health Organization declared the spread of the coronavirus a pandemic… By data American Johns Hopkins University, as of December 25, almost 79.5 million people were infected with the coronavirus in the world. More than 1.74 million people have died from COVID-19 and more than 44.8 million patients have recovered. In Turkey, the number of cases since the beginning of the pandemic has exceeded 2.1 million, 1.9 million people have been recovered, 19.1 thousand have died.
By data WHO, as of December 22, the world’s 61 COVID-19 vaccine manufacturers are candidates for clinical evaluation of the drug. 172 companies perform preclinical tests.
[ad_2]
